Tags

Type your tag names separated by a space and hit enter

Trial of Edmonston-Zagreb measles vaccine in infants aged under nine months.
Southeast Asian J Trop Med Public Health. 1991 Sep; 22(3):347-50.SA

Abstract

Due to the recent finding that most infants in developing countries have lost maternal antibody for measles before nine months of age, immunization of infants younger than the recommended age of nine months would help reducing the incidence of measles in these endemic areas. We conducted a trial of Edmonston-Zagreb measles vaccine which is the strain that may be more immunogenic in young infants than the widely used Schwarz strain. Forty-five infants with mean age of 25 weeks received a dose of Edmonston-Zagreb vaccine. Antibody levels were measured, using plaque neutralization test, before and about 3 months after vaccination at which mean age was 38 weeks. The seroconversion rate was 89%. Only two infants (4.4%) had immunity before vaccination. Fifteen infants (33.33%) reported some adverse reactions including fever (13.33%), rhinorrhea (8.89%), rash (4.44%) and local reactions (22.22%). All of the reactions resolved spontaneously. We conclude that Edmonston-Zagreb measles vaccine is efficacious and safe in infants aged under nine months.

Authors+Show Affiliations

Department of Pediatrics, Maharaj Nakhon Ratchasima Hospital, Thailand.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

1818384

Citation

Pongrithsukda, V, et al. "Trial of Edmonston-Zagreb Measles Vaccine in Infants Aged Under Nine Months." The Southeast Asian Journal of Tropical Medicine and Public Health, vol. 22, no. 3, 1991, pp. 347-50.
Pongrithsukda V, Gluck R, Suwatanapongched S, et al. Trial of Edmonston-Zagreb measles vaccine in infants aged under nine months. Southeast Asian J Trop Med Public Health. 1991;22(3):347-50.
Pongrithsukda, V., Gluck, R., Suwatanapongched, S., Kaewmalung, P., & Muyakul, J. (1991). Trial of Edmonston-Zagreb measles vaccine in infants aged under nine months. The Southeast Asian Journal of Tropical Medicine and Public Health, 22(3), 347-50.
Pongrithsukda V, et al. Trial of Edmonston-Zagreb Measles Vaccine in Infants Aged Under Nine Months. Southeast Asian J Trop Med Public Health. 1991;22(3):347-50. PubMed PMID: 1818384.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Trial of Edmonston-Zagreb measles vaccine in infants aged under nine months. AU - Pongrithsukda,V, AU - Gluck,R, AU - Suwatanapongched,S, AU - Kaewmalung,P, AU - Muyakul,J, PY - 1991/9/1/pubmed PY - 1991/9/1/medline PY - 1991/9/1/entrez SP - 347 EP - 50 JF - The Southeast Asian journal of tropical medicine and public health JO - Southeast Asian J Trop Med Public Health VL - 22 IS - 3 N2 - Due to the recent finding that most infants in developing countries have lost maternal antibody for measles before nine months of age, immunization of infants younger than the recommended age of nine months would help reducing the incidence of measles in these endemic areas. We conducted a trial of Edmonston-Zagreb measles vaccine which is the strain that may be more immunogenic in young infants than the widely used Schwarz strain. Forty-five infants with mean age of 25 weeks received a dose of Edmonston-Zagreb vaccine. Antibody levels were measured, using plaque neutralization test, before and about 3 months after vaccination at which mean age was 38 weeks. The seroconversion rate was 89%. Only two infants (4.4%) had immunity before vaccination. Fifteen infants (33.33%) reported some adverse reactions including fever (13.33%), rhinorrhea (8.89%), rash (4.44%) and local reactions (22.22%). All of the reactions resolved spontaneously. We conclude that Edmonston-Zagreb measles vaccine is efficacious and safe in infants aged under nine months. SN - 0125-1562 UR - https://www.unboundmedicine.com/medline/citation/1818384/Trial_of_Edmonston_Zagreb_measles_vaccine_in_infants_aged_under_nine_months_ L2 - https://www.diseaseinfosearch.org/result/4535 DB - PRIME DP - Unbound Medicine ER -